- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001228
Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer
Evaluation of Treatment With Interferon, Octreotide, or Their Combination in Patients With Zollinger-Ellison Syndrome and Progressive Metastatic Non-B Islet Cell Neoplasm
This study will examine the safety and effectiveness of interferon-a and octreotide for the treatment of Zollinger-Ellison syndrome (gastrinoma) and advanced non-B islet cell cancer. Gastrinoma is a tumor produced by the pancreas that secretes the hormone gastrin, which in turn stimulates production of gastric juices that cause ulcers. Some of these tumors are malignant. Gastrinomas that have spread and cannot be surgically removed require drug treatment (chemotherapy). Current drug regimens, however, provide only temporary benefit and, in some cases, produce life-threatening side effects. In studies of patients with tumors similar to gastrinoma, the drugs octreotide and interferon-a, alone or in combination, showed some effect in stopping tumor growth and were better tolerated than chemotherapy. At least one-third of patients responded to treatment with either drug for at least 6 months; the two drugs given together may produce a better response than either one alone.
Patients currently enrolled in an NIH study of Zollinger-Ellison syndrome whose gastrinoma has spread from the original site and cannot be surgically removed may be eligible for this study.
Participants will be admitted to the NIH Clinical Center for blood and urine tests, electrocardiogram (EKG), chest X-ray and imaging studies (CT, ultrasound, MRI, octreoscan, and bone scan) before beginning treatment to evaluate the size and extent of tumors. Patients will then start interferon-a or octreotide, or both, given as injections under the skin. Treatment will continue for at least 6 months, unless side effects require stopping the drugs early. Patients whose tumors shrink or remain stable may continue treatment indefinitely. Those who do not respond to treatment will be taken off the study and offered standard chemotherapy.
Patients will be admitted to the hospital for the first day or two of therapy to be monitored for side effects and to learn how to self-inject the drugs to continue therapy at home. Both drugs are given [Note: how often? once a day, twice a day, weekly?] (Octreotide is also available in long-acting form, and patients who prefer may be given this drug once a month by the doctor.)
During the treatment period, patients will be seen by their personal physician every 2 weeks for the first month and once a month thereafter for a medical evaluation and check of adverse side effects of treatment. In addition, they will be admitted to the NIH Clinical Center once every 3 months for a medical evaluation and imaging studies, including CT, MRI, ultrasound, bone scan, and octreoscan, to assess the effect of treatment on tumor size.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA
Subjects selected for this study will be patients with Zollinger-Ellison syndrome who are being evaluated under the protocol entitled "Diagnostic evaluation of patients with suspected abnormalities of gastric secretion" (80-DK-123). To be entered into the study a patient must meet each of 3 criteria:
- histologically proven gastrinoma;
- evidence of metastatic tumor by one or more of angiography, ultrasound, computerized axial tomography, bone scan or octreoscan;
- progression of tumor size during the preceding 6 months as assessed by repeated imaging studies.
EXCLUSION CRITERIA
For treatment with interferon-(alpha):
- Congestive heart failure
- Proteinuria, 3 + or greater
- Creatinine clearance less than 30 ml/min
- Platelet count less than 30 x 10(9)/1
- White blood count less than 4 x 10(9)/1
- Bilirubin greater than 3 mg/dl
- Positive test for HIV antibody
- Pregnancy
For treatment with octreotide:
1. Presence of cholelithiases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Disease
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Intestinal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Pancreatic Diseases
- Paraneoplastic Syndromes
- Pancreatic Neoplasms
- Carcinoma, Islet Cell
- Paraneoplastic Endocrine Syndromes
- Syndrome
- Adenoma
- Adenoma, Islet Cell
- Gastrinoma
- Zollinger-Ellison Syndrome
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Interferons
Other Study ID Numbers
- 880194
- 88-DK-0194
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Zollinger Ellison Syndrome
-
National Institute of Diabetes and Digestive and...CompletedGastrinoma | Zollinger Ellison SyndromeUnited States
-
National Institute of Diabetes and Digestive and...CompletedZollinger Ellison SyndromeUnited States
-
National Institute of Diabetes and Digestive and...Completed
-
National Institute of Diabetes and Digestive and...CompletedGastrinoma | Zollinger Ellison Syndrome | AchlorhydriaUnited States
-
National Institute of Diabetes and Digestive and...CompletedNeoplasm Metastasis | Zollinger Ellison Syndrome | Islet Cell AdenomaUnited States
-
AstraZenecaCompletedGastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison SyndromeJapan
-
AstraZenecaCompletedZollinger-Ellison SyndromeUnited States, France
-
Trio Medicines Ltd.National Institutes of Health (NIH)TerminatedZollinger-Ellison Syndrome
-
Charles Mel Wilcox, MDTakeda Pharmaceuticals North America, Inc.CompletedZollinger-Ellison Syndrome | Multiple Endocrine Neoplasia
-
AstraZenecaCompletedZollinger-Ellison Syndrome | Reflux Esophagitis (RE) | Gastric Ulcer (GU) | Duodenal Ulcer (DU) | Anastomotic Ulcer (AU) | Non-erosive Reflux Esophagitis Disease (NERD)Japan
Clinical Trials on Interferon
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Horizon Pharma USA, Inc.TerminatedMyxoid Liposarcoma | Synovial Sarcoma | Round Cell LiposarcomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Mongolian National University of Medical SciencesMongolian National Cancer CenterRecruitingHPV Infection | Cervical DysplasiaMongolia
-
Digna Biotech S.L.CompletedChronic Hepatitis C Virus Infection | Genotype 1 | Treatment-Experienced Patients | RelapsesSpain
-
Royal Marsden NHS Foundation TrustCompleted
-
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.CytoPharm, Inc.Completed
-
Minneapolis Veterans Affairs Medical CenterUS Department of Veterans Affairs; Kadmon Corporation, LLC; InterMune; San Diego... and other collaboratorsCompletedChronic Hepatitis C
-
SPP Pharmaclon Ltd.RecruitingPulmonary TuberculosisRussian Federation
-
SPP Pharmaclon Ltd.CompletedCommunity-acquired PneumoniaRussian Federation
-
The Cleveland ClinicNational Cancer Institute (NCI)CompletedMelanoma | Sarcoma | Lymphoma | Kidney Cancer | Breast Cancer | Multiple Myeloma | Unspecified Adult Solid Tumor, Protocol SpecificUnited States